Department of OBGYN

Katherine Bunge, MD, MPH

  • Assistant Professor, Department of Obstetrics, Gynecology & Reproductive Sciences

Education & Training

  • Fellowship, Magee Womens Hospital,Reproductive Infectious Diseases, Pittsburgh, PA
  • Residency, Northwestern Memorial Hospital, Chicago, IL
  • MD, Johns Hopkins School of Medicine, Baltimore, MD
  • MPH, Johns Hopkins School of Medicine, Baltimore, MD

Representative Publications

  • Bunge KE, Macio I, Meyn L, Noguchi L, Parniak M, Schwartz J, Moncla B, Hillier S. The Safety, Persistence, and Acceptability of an Antiretroviral Microbicide. JAIDS 2012 Aug 1;60(4):337-43. PMIC: 22495787.
  • Dezzutti CS, Uranker K, Bunge KE, Richardson-Harman N, Macio I, Hillier SL. HIV-1 infection of female genital tract tissue for use in prevention studies. J Acquir Immune Defic Syndr. 2013 Aug 15:63 (5): 548-54. Doi:10.1097/ AQI.0b013e3182911331. PMID: 23514957.
  • Bunge KE, Dezzutti CS, Rohan LC, Hendrix CW, Marzinke MA, Richardson-Harman N, Moncla BJ, Devlin B, Meyn LA, Spiegel HM, Hillier SL. A phase 1 trial to assess the safety, acceptability, pharmacokinetics, and pharmacodynamics of a novel dapivirine vaginal film. J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):498-505. doi: 10.1097/QAI.0000000000000897. PMID: 26565716.
  • Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, Mgodi NM, Matovu Kiweewa F, Nair G, Mhlanga F, Siva S, Bekker LG, Jeenarain N, Gaffoor Z, Martinson F, Makanani B, Pather A, Naidoo L, Husnik M, Richardson BA, Parikh UM, Mellors JW, Marzinke MA, Hendrix CW, van der Straten A, Ramjee G, Chirenje ZM, Nakabiito C, Taha TE, Jones J, Mayo A, Scheckter R, Berthiaume J, Livant E, Jacobson C, Ndase P, White R, Patterson K, Germuga D, Galaska B, Bunge K, Singh D, Szydlo DW, Montgomery ET, Mensch BS, Torjesen K, Grossman CI, Chakhtoura N, Nel A, Rosenberg Z, McGowan I, Hillier S; MTN-020–ASPIRE Study Team. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016 Feb 22. [Epub ahead of print].

Clinical Interests/Research Interests

Dr. Bunge’s primary research responsibilities are housed within the Microbicide Trials Network (MTN), an NIH funded HIV prevention network. She serves as a Safety Physician overseeing the pharmacovigilance activities within the MTN studies. In addition, she has served as the protocol co-chair for two adolescent trials within the MTN examining the safety and acceptability of vaginal microbicides in a teen population. Under the auspices of the MTN, she works closely with the Contraceptive Action Team to expand the contraceptive methods mix at HIV prevention research sites. Outside of the network, she runs the clinical trials within a U19 evaluating novel film formulations for the delivery of antiviral microbicide products.

Dr. Bunge's specific research interests are:

  • Safety of vaginal microbicide products
  • Expanding contraceptive options in HIV prevention trials
  • Development of alternative microbicide formulations